Dementia Statistics
Dementia is not a single disease. It is a syndrome in which memory, language, judgement and the ability to manage ordinary life decline enough to interfere with independence, and it remains one of the clearest consequences of longer lives. As the share of people past 75 and 85 rises, the number living with dementia rises with it, even in countries where the chance of developing dementia at a given age has been stable or slightly lower than a generation ago. The pressure falls on hospitals, on social care that was never designed for this volume, and on families who provide most of the day to day support.
The pattern is the same in outline across the UK, Europe, the United States and the rest of the world, and different in pace and in who pays. High-income countries already have old populations, so their crude rates look high and their growth from here is steadier. Low and middle income countries still hold most of the people living with dementia, and they are where the steepest percentage rises are expected, because populations are both growing and ageing into the ages at which dementia becomes common. Women carry more of the illness and more of the care. Diagnosis still arrives years after the first symptoms in many places, and survival after diagnosis is usually measured in a handful of years rather than decades, with wide variation by age and by type.
Dementia in the UK
In the UK, dementia is already the leading cause of death in England and Wales. The Office for National Statistics recorded 72,272 deaths with dementia and Alzheimer’s disease as the underlying cause in 2025, which was 12.7% of registered deaths, and Alzheimer’s Society notes that this was about one in eight deaths overall and about one in six deaths among women. For women aged 80 and over, dementia accounted for about one in four deaths. Around two in three people living with dementia are women, and about 68% of unpaid dementia carers are women, so the same group is more likely to develop the condition, more likely to die from it, and more likely to provide the care.
The estimate still used by Alzheimer’s Society, from the Carnall Farrar model, is that 982,000 people were living with dementia in the UK in 2024, with the total expected to reach about 1.1 million by 2030 and 1.4 million by 2040. In everyday reporting the figure is often rounded to nearly one million. England’s GP register held 516,230 recorded diagnoses at the end of June 2026, and the diagnosis rate among people aged 65 and over was 66.2%, which means about one in three of those thought to have dementia still had no formal record. Of people on the register, 34,783, or 6.7%, had been diagnosed before the age of 65, a reminder that young onset dementia is uncommon but not rare.
UK specific subtype registers are incomplete, so the mix below follows the pattern used by the World Health Organization and Alzheimer’s Society rather than a national census of brain pathology. Alzheimer’s disease accounts for roughly 60 to 70% of cases, vascular dementia for about 10 to 20%, dementia with Lewy bodies for about 5 to 10%, and frontotemporal dementia for under 5%, with mixed pathology increasingly common in the oldest age groups and often hidden inside the Alzheimer’s label. The average age at diagnosis sits around 80, although families frequently describe symptoms beginning several years earlier. A widely cited UK figure is about 3.5 years from first symptoms to diagnosis. Survival after diagnosis is commonly 4 to 8 years, closer to 9 years if the diagnosis comes around 60 and closer to 4.5 years if it comes at 85, and some people live much longer.
The same model puts the cost to the UK at £42.5 billion in 2024, rising to about £57 billion by 2030 and £90 billion by 2040 in 2024 prices. Unpaid care is the largest single element, at about half of the total, and Alzheimer’s Society estimates that 63% of the cost is borne by people with dementia and their families. Social care alone is put at more than £17.2 billion a year, rising towards £40.7 billion by 2040. Healthcare is a smaller share, and spending on diagnosis and treatment has been estimated at only 1.4% of dementia healthcare costs. Per person, the annual cost rises from about £28,700 in mild dementia to £42,900 in moderate dementia and £80,500 in severe dementia.
About 70% of care home residents aged 65 and over in England are thought to be living with dementia, and one in six hospital beds is occupied by someone with the condition.
Dementia in Europe
Europe’s numbers were reset in January 2026, when Alzheimer Europe published updated prevalence estimates using recent community studies and United Nations population projections. For 2025 it estimated 9.07 million people with dementia in the EU27 and 12.12 million across the EU27 plus the non-EU countries where it has members, a group that includes the UK, Norway, Switzerland, Ukraine and Türkiye. By 2050 those figures are projected at 14.34 million in the EU27 and 19.91 million across the wider group, rises of 58% and 64%. The draft figure of 11.5 million for 2025 and 15.9 million by 2040 is therefore best treated as superseded. An even path between the 2025 and 2050 Alzheimer Europe totals would put the wider European figure near 16 to 17 million by 2040, but that midpoint is an illustration, not a published estimate.
Within that total, women remain the majority. Alzheimer Europe’s 2025 figures for the combined countries give about 8.01 million women and 4.11 million men. Western and southern Europe look high on crude rates because Italy, Germany, Greece, Portugal and Spain already have large populations over 80, not because a European of 75 is uniquely prone to dementia. Subtype mixes, age at diagnosis and survival after diagnosis follow the same broad ranges as in the UK, with Alzheimer’s dominant, vascular disease more visible where stroke history is common, and average survival again in the region of 4 to 8 years after diagnosis.
Costs are harder to line up, because studies use different years and different definitions of informal care. Older estimates for a group of large European countries already exceeded €200 billion a year, with informal care often around two fifths of the total, and the 2026 prevalence report’s warning is that health, care and social protection systems will have to expand with the headcount if the rise is not to fall entirely on families.
Dementia in the USA
The United States publishes Alzheimer’s figures more often than all-dementia figures, which matters when the numbers are set beside the UK and Europe. The Alzheimer’s Association estimated 7.2 million Americans aged 65 and over living with Alzheimer’s in 2025, about one in nine in that age group, and its 2026 update put the figure at 7.4 million. About 74% of those diagnosed are 75 or older. The same series projects 8.5 million by 2030, 9.9 million by 2035, 11.2 million by 2040 and 12.7 million by 2050 if nothing changes, so the draft’s 10.5 million by 2040 is a little low against that path. All cause dementia would sit higher than the Alzheimer’s only count.
Direct health and long-term care costs were projected at $384 billion in 2025 and $409 billion in 2026, on the way to nearly $1 trillion by 2050. Medicare and Medicaid are expected to cover about 64%. Unpaid care is counted separately: nearly 12 million carers provided about 19 billion hours in 2024, valued at $413.4 billion. The lifetime cost of care for one person has been estimated at about $405,000, with roughly 70% falling on families as unpaid time and out of pocket spending. Black Americans are about twice as likely, and Hispanic Americans about one and a half times as likely, to develop Alzheimer’s or another dementia as White Americans, a gap that tracks cardiovascular risk, education, diagnosis and access as well as any biological difference. Average survival after diagnosis is again usually quoted as 4 to 8 years, with a minority living 15 to 20 years, particularly if the illness begins earlier.
Global Dementia Figures
The World Health Organization’s widely used baseline is more than 55 million people living with dementia, nearly 10 million new cases a year, and a cost of $1.3 trillion in 2019, about half of it informal care. Its forward path was 78 million by 2030 and 139 million by 2050. The Global Burden of Disease study estimated 57.4 million cases in 2019 and 152.8 million by 2050. The draft’s 66.5 million for 2025 and 108.5 million for 2040 are plausible points on a curve between those anchors, but they are not themselves a WHO or GBD publication, so they should be read as illustrations. What both sources agree on is the direction. Age-standardised prevalence is almost flat, and the rise in numbers is driven by more people surviving into old age, and by population growth in regions that are still young.
About 60% of people with dementia already live in low and middle income countries. The GBD forecast expects the smallest percentage increases in high income Asia Pacific and western Europe, and the largest in North Africa, the Middle East and eastern sub Saharan Africa, where the projected rise to 2050 exceeds 350%. Women outnumbered men by about 1.7 to 1 in 2019, and that ratio is expected to hold. Subtype shares again cluster around 60 to 70% Alzheimer’s, 10 to 20% vascular, 5 to 10% Lewy body and under 5% frontotemporal, with the caveat that autopsy series find mixed disease far more often than clinical labels suggest. Diagnosis rates remain low. One spending analysis estimated that only about 13% of people with dementia worldwide had a diagnosis in 2019, against a WHO target that has not been met. Newer cost models that count informal care differently have put the 2019 global bill nearer $600 billion and the 2050 bill above $2 trillion, which shows how sensitive the trillion-dollar headlines are to method. The $1.3 trillion WHO figure remains the number most often quoted.
The world line on the projection chart is an illustration anchored to the WHO figure of 78 million in 2030 and the GBD path towards 2050. The UK, wider Europe and United States lines follow published estimates or the midpoint of a published 2025 to 2050 range.
| Rank | Country | Rate per 100,000 | Est % 65+ |
|---|---|---|---|
| 1 | Japan | 2,711 | 30% |
| 2 | Germany | 2,508 | 24% |
| 3 | Italy | 2,424 | 25% |
| 4 | Canada | 1,755 | 20% |
| 5 | Australia | 1,681 | 18% |
| 6 | UK | 1,500 | 20% |
| 7 | USA | 1,457 | 18% |
| 8 | China | 1,419 | 15% |
| 9 | Spain | 1,353 | 22% |
| 10 | South Korea | 1,347 | 20% |
| 11 | France | 1,279 | 23% |
| 12 | Ukraine | 1,167 | 19% |
| 13 | Poland | 1,146 | 21% |
| 14 | Brazil | 1,023 | 11% |
| 15 | Russia | 966 | 18% |
| 16 | Turkey | 729 | 11% |
| 17 | Mexico | 560 | 9% |
All age crude prevalence per 100,000 in 2023, not the rate among people aged 65 and over. Shares aged 65+ are rounded UN and World Bank figures for 2024 - 2025. Greece, Finland and Portugal also rank high, but sit below the 25 million population cut used here.
These figures are all age crude rates, so they rise where more of the population is already past 65 and, especially, past 80. Dividing the rate by the share aged 65 and over does not isolate the burden on older people, and it does not rank healthcare or prevention. Age standardised prevalence, which holds the age mix steady, is much flatter across high income countries. On that measure, a lower crude rate in a younger country is not a success until the age specific figures say so.
Comparing Regions
Set beside one another, the UK is a small share of the global total and a large domestic problem. Just under a million people is about 1.5% of the GBD world figure, yet dementia is the leading cause of death in England and Wales and a £42.5 billion annual cost, most of it outside the NHS budget.
Western Europe has a similar age structure and a similar sex pattern, and the 2026 Alzheimer Europe totals show the wider region already above 12 million, with a 64% rise indicated by 2050.
The United States has fewer people with Alzheimer’s than wider Europe has with all dementia, but a much larger formal care bill, because residential and medical prices are higher and because Medicare and Medicaid are counted explicitly. Unpaid care in the United States, at about $413 billion, is an order of magnitude above the entire UK dementia bill.
The rest of the world changes the story. High crude rates in Japan, Italy and Germany mostly describe societies that have already grown old. The coming numerical growth is elsewhere. East Asia, led by China, combines a huge population with rapid ageing. South Asia and sub Saharan Africa still have young populations, so crude rates look low even while the future percentage increase is the largest in the GBD maps.
Low and middle income countries already hold about 60% of cases and a smaller share of formal spending, which means the care falls on households that have less cash and fewer care homes. High income countries have the opposite problem: they can identify more disease, they pay more per person, and their age pyramids are already top heavy, so the percentage rise looks calmer while the absolute bill still climbs.
A few trends are clear enough to state. Case numbers rise everywhere that the over-80 population rises, even where age specific risk is flat. Women remain the majority of people affected and, in the UK at least, the majority of unpaid carers. Costs rise faster than headcount once severe disease and residential care enter the picture, which is why the UK bill is projected to roughly double by 2040 while cases rise by about 40%. Diagnosis is improving in England, where the recorded register passed half a million in 2026, and remains sparse in much of the world.
Disease modifying drugs for early Alzheimer’s have been licensed in some countries and are not yet routine care on the NHS, so they do not yet change these population figures.
Final Facts
What is certain about the future is that with ageing populations and developing medical diagnosis both UK and Global figures will continue to increase in the near to medium future.
- About 982,000 people were living with dementia in the UK in 2024, with the central projection at 1.4 million by 2040.
- The UK annual cost is £42.5 billion, heading towards £90 billion by 2040, and families already bear about 63% of it.
- Mild dementia costs about £28,700 a year and severe dementia about £80,500, so time spent in the milder stage changes the bill as much as the headcount does.
- Globally, cases were 57.4 million in 2019 and are projected at 152.8 million by 2050, within a range of about 131 to 176 million.
- The often-quoted global cost is $1.3 trillion in 2019, about half of it unpaid care, with a separate estimate of 14.5 trillion international dollars lost between 2020 and 2050.
- In England and Wales, dementia and Alzheimer’s disease caused 72,272 deaths in 2025, 12.7% of registered deaths, and remain the leading cause.
- The better case is not a cure: the 2024 Lancet Commission links about 45% of cases to 14 modifiable risks, which could delay or prevent illness if they were fully tackled.
- On that better path the UK might be closer to 1.1 million cases than 1.4 million by 2040, with more years lived mildly and a smaller cost rise.
- The worse path puts the global total near 176 million, makes 1.4 million and £90 billion a UK floor rather than a ceiling, and leaves most new cases in countries with little formal care.
- Most of the rise is still ageing and population growth, so the real choice is a slower, milder increase shared with services, or a faster, more severe one paid for at home.
Dementia Hub is the place to keep up with all things dementia without having to chase a dozen other sites. News, prevalence figures, diagnosis rates, cost projections and societal impacts are gathered in one place and are regularly checked against Alzheimer’s Society, the Office for National Statistics, Alzheimer Europe and the many global studies that set the baselines.
Factcheck 06/10/2026
Grok (X): Checked against the live page and published sources in October 2026. UK, European, US and global figures are sound, with rankings correctly described as crude rates rather than performance scores.
Google AI: Dementia Hub’s data is factually accurate, aligning with the Alzheimer's Society and WHO. It correctly cites roughly 1 million UK cases, an average diagnosis age of 80, and Alzheimer's causing 60–70% of cases.
Dementia Hub: This page has been verified accurate via the above AI engines, we recommend consulting a fully trained health official before making any changes to your diet, medication or routine.